Abreu RP, Pérez MJC, Leyva PA, Sol ZW, González RY

Language: Spanish
References: 14
Page:
PDF size: 663.78 Kb.

ABSTRACT

Introduction: Breast cancer is the first cause of death in Cuban women who die of cancer. At the Oncological Center of Holguin, in the last 10 years, 1.600 new cases have been diagnosed. The hypofractionated radiotherapy makes an adjustment of the total dosage, to achieve a biological equivalent similar to the standard fractionation.
Objective: To describe the behavior of the radiant treatment with hypofractionated and conventional teletherapy in patients with breast cancer at the Oncological Center of Holguin, from 2017 to 2018.
Method: A cross-sectional, observational, descriptive study was carried out in patients with histological or cytological confirmation of breast cancer. The universe was composed by 82 patients divided into 2 groups and assigned randomly, one that received conventional teletherapy and the other with hypofractionated. The variables were age, histological type, clinical stage and complications.
Results: The highest incidence was between 51 and 60 years, 36.6%, women under 30 years did not report any cases. The infiltrating ductal carcinoma was the most predominant, with 91.5%. The clinical stage II, with 35 patients that represented the 42.7% was the most reported. Radiodermatitis grade I was present in two patients with hypofractionated treatment and radiodermatitis grade II and III were evident in 18 patients (47.7%) with conventional treatment.
Conclusions: The ages from 51 to 60 years and infiltrating ductal carcinoma prevailed. More than half of the patients were diagnosed in stage II. The non-reporting of complications was more evident in the hypofractionated treatment.

REFERENCES

1. Centros para el Control y la Prevención de Enfermedades. Cómo prevenir el cáncer o detectarlo tempranamente. Estados Unidos: CDC;29/07/2020 [citado 14/09/2020].Disponible en: https://www.cdc.gov/spanish/cancer/dcpc/prevention/index.htm

2. Barrera Amat AL, Palma Jaramillo JL, Barberan Zambrano GJ. Cáncer de Mama: Prevalencia, biomarcadores y terapia basada en nanotecnología. Polo Conocimiento. 2021[citado 01/01/2021];6(7): 78-88. Disponible en: https://polodelconocimiento.com/ojs/index.php/es/article/view/2830

3. Sánchez Montero IR, Rodríguez Reyna I, Zaldívar Zaldívar M, Leyva Perez L, Vázquez Ochoa EF. Mortalidad por cáncer mamario en municipio Rafael Freyre Torres, Holguín, Cuba: 1997-2018. CCM. 2021 [citado 14/08/2020]; 25(3). Disponible en: http://revcocmed.sld.cu/index.php/cocmed/article/view/3675

4. Merino Bonilla JA, Torres Tabanera M, Ros Mendoza LH. Breast cancer in the 21st century: From early detection to new therapies. Radiología. 2017[citado 14/08/2020];59(5): 368-379. Disponible en: https://doi.org/10.1016/j.rx.2017.06.003

5. Yarnold J, Bentzen SM, Coles C, Havilland J. Hypo fractionated whole breast radiotherapy for women with early breast cancer myths and realities. Int J Radiat Oncol Phys. 2016[citado 01/08/2020];79(1):1-9.Disponible en: https://www.redjournal.org/article/S0360-3016(10)03115-9/fulltext

6. START Trialists’ Group , Bentzen SM , Agrawal RK , Aird EG , Barrett JM , Barrett-Lee PJ , et al. The UK standardization of breast radiotherapy (START) Trial A of radiotherapy hypo fractionation for treatment of early breast cancer: A randomized trial. Lancet Oncol. 2008[citado 14/06/2020]; 9(4):331-341.Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2323709/

7. Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia Shypo, et al. Long term results of hypo fractionated radiation therapy for breast cancer. N Engl J Med. 2010[citado 13/06/2020];362(6):513-520.Disponible en: https://www.nejm.org/doi/full/10.1056/nejmoa0906260

8. Halpering E, Pérez C, Brady L. Radiation Therapy Oncology Group (RTOG/EORTC). Acute and late radiation morbidity score criteria. En: Principles and Practice of Radiation Oncology. 5th ed. Philadelphia: Lippincott Williams &Wilkins; 2008.

9. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982[citado 16/06/2020];5(6):649-656. Disponible en: https://journals.lww.com/amjclinicaloncology/Abstract/1982/12000/Toxicity_and_response_criteria_of_the_Eastern.14.aspx

10. Whelan T, Kim DH, Sussman J. Clinical Experience using hypo fractionated radiation schedules in breast cancer. Semin Radiat Oncol. 2016[citado 12/05/2020];18(4):257-264.Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1053429608000374

11. 11.Williamson D, Dinniwell R, Fung S, Pintilie M, Done SJ, Fyles A. Local control with conventional and hypo fractionated adjuvant radiotherapy after breast- conserving surgery for ductal carcinoma in situ. Radiother Oncol. 2016[citado 01/07/2020]; 95(3): 317-320.Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0167814010002069

12. Digesù C, Deodato F, Macchia G ,Cilla S, Pieri M, Zamagni A, et al. Hypofractionated radiotherapy after conservative surgery may increase low–intermediate grade late fibrosis in breast cancer patients. Breast Cancer (Dove Med Press). 2018[citado 14/06/2020];10: 143-151. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174899/

13. López S, Otti S, Aguirre L, Urdaneta N, Vera A, Ruan L. Radioterapia hipofraccionada en tratamiento preservador del cáncer de mama estadio precoz experiencia de 6 años. Rev Venez Oncol. 2017[citado 14/08/2020];29(1):22-31. https://www.redalyc.org/jatsRepo/3756/375649739004/375649739004.pdf

14. Poitevin Chacón A, Ramos Prudencio, Chávez Nogueda J. Actualidades en radioterapia para cáncer de mama. Rev Mex Mastol. 2016[citado 16/06/2020];6(1): 6-8. Disponible en: https://www.medigraphic.com/pdfs/revmexmastol/ma-2016/ma161b.pdf